Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 6 hours ago
- 1 min read
16/06/2026
Avalo Therapeutics added AVTX-010, a long-acting next-generation anti-IL-1β antibody, to Its development pipeline (Ref)
Avalo Therapeutics announced the advancement of AVTX-010 (anti-IL-1β mAb) with the potential for development in hidradenitis suppurativa (HS) as well as additional inflammatory disorders.
The Company expected to submit an Investigational New Drug application for AVTX-010 in H1 of 2027.
